Search Clinical Trials
Our researchers are currently in need of adult and pediatric study participants to help us pursue better treatments and cures. Participants may receive medical evaluations and procedures, study medication, disease-related education and possible financial compensation for time, travel and participation.
Select a Condition or Specialty
- Allergy
- Alpha-1 Antitrypsin Deficiency
- Asthma
- Cardiology
- Chronic Obstructive Pulmonary Disease (COPD)
- COVID-19 (Coronavirus)
- Cystic Fibrosis
- Eczema (Atopic Dermatitis)
- Environmental & Occupational Health
- Food Allergy
- Gastroenterology
- Idiopathic Pulmonary Fibrosis (IPF)
- Interstitial Lung Disease (Pulmonary Fibrosis)
- Lung Cancer
- Oncology
- Pulmonary Hypertension (PH)
- Respiratory (Pulmonary)
- Rheumatology
- Sarcoidosis
All Clinical Trials
.jpg?lang=en-US&ext=.jpg)
Improving Treatment for IPF
Researchers want to know if a new medication, Saracatinib, is a more safe and effective treatment for Idiopathic Pulmonary Fibrosis (IPF) when compared to treatments that are currently available.
- Gender
- Any
- Ages
- 40+
- Compensation
- Not Provided
- Time Required
- Not Specified

Pulmonary Fibrosis & Genetic Factors
The purpose of this study is to investigate inherited genetic factors that play a role in the development of familial pulmonary fibrosis and to identify a group of genes that predispose individuals to develop pulmonary fibrosis.
- Gender
- Any
- Ages
- Not Specified
- Compensation
- Not Provided
- Time Required
- Not Specified
.jpg?lang=en-US&ext=.jpg)
IPF COMFORT Study for Chronic Cough
The IPF COMFORT Study is a clinical research study in patients with coughing attributed to Idiopathic Pulmonary Fibrosis.
- Gender
- Any
- Ages
- 40+
- Compensation
- Provided
- Time Required
- Six study appointments over 17 weeks, with clinic visits every three to four weeks

BBT-877: Possible Treatment for Idiopathic Pulmonary Fibrosis
Idiopathic pulmonary fibrosis (IPF) currently affects millions of people globally, and current treatments such as pirfenidone or nintedanib are often poorly tolerated in some patients due to frequently associated side effects. Researchers want to know if an investigational medication called BBT-877, either alone or in conjunction with other therapies, may help slow lung function decline.
- Gender
- Any
- Ages
- 40+
- Compensation
- Provided
- Time Required
- Six clinic visits over up to 34 weeks
Adult Trials
.jpg?lang=en-US&ext=.jpg)
Improving Treatment for IPF
Researchers want to know if a new medication, Saracatinib, is a more safe and effective treatment for Idiopathic Pulmonary Fibrosis (IPF) when compared to treatments that are currently available.
- Gender
- Any
- Ages
- 40+
- Compensation
- Not Provided
- Time Required
- Not Specified

Pulmonary Fibrosis & Genetic Factors
The purpose of this study is to investigate inherited genetic factors that play a role in the development of familial pulmonary fibrosis and to identify a group of genes that predispose individuals to develop pulmonary fibrosis.
- Gender
- Any
- Ages
- Not Specified
- Compensation
- Not Provided
- Time Required
- Not Specified

BBT-877: Possible Treatment for Idiopathic Pulmonary Fibrosis
Idiopathic pulmonary fibrosis (IPF) currently affects millions of people globally, and current treatments such as pirfenidone or nintedanib are often poorly tolerated in some patients due to frequently associated side effects. Researchers want to know if an investigational medication called BBT-877, either alone or in conjunction with other therapies, may help slow lung function decline.
- Gender
- Any
- Ages
- 40+
- Compensation
- Provided
- Time Required
- Six clinic visits over up to 34 weeks
Pediatric Trials
Healthy Participant Trials
.jpg?lang=en-US&ext=.jpg)
IPF COMFORT Study for Chronic Cough
The IPF COMFORT Study is a clinical research study in patients with coughing attributed to Idiopathic Pulmonary Fibrosis.
- Gender
- Any
- Ages
- 40+
- Compensation
- Provided
- Time Required
- Six study appointments over 17 weeks, with clinic visits every three to four weeks